Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.090
-0.030 (-1.42%)
Aug 6, 2026, 12:37 PM EDT - Market open
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
n/a
Profits / Employee
-$1,725,071
Market Cap
362.78M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 161 |
| Zentalis Pharmaceuticals | 106 |
| Agenus | 81 |
| Century Therapeutics | 78 |
| Upstream Bio | 75 |
| Lexeo Therapeutics | 59 |
| Vicore Pharma Holding AB | 40 |
| Compass Therapeutics | 39 |
PALI News
- 5 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 14 days ago - Palisade Bio initiated with an Outperform at Oppenheimer - TheFly
- 24 days ago - Palisade Bio management to meet with Piper Sandler - TheFly
- 27 days ago - Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - GlobeNewsWire
- 5 weeks ago - Palisade Bio receives FDA clearance to start ulcerative colitis study - TheFly
- 5 weeks ago - Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis - GlobeNewsWire
- 2 months ago - Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors - GlobeNewsWire
- 2 months ago - Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium - GlobeNewsWire